A p34cdc2 survival checkpoint in cancer

Cancer Cell

Volumn 2, Issue 1, 2002, Pages 43-54

  O'Connor, Daniel S ^a   Wall, Nathan R ^a   Porter, Andrew C G ^b   Altieri, Dario C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALSTERPAULLONE; APOPTOSIS INHIBITOR; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; OLOMOUCINE; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P 34 CDC2 KINASE; PROTEIN P53; PURVALANOL A; RNA; STABILIZING AGENT; SURVIVIN; UNCLASSIFIED DRUG; VINCRISTINE; 6 ((3 CHLORO)ANILINO) 2 (ISOPROPYL 2 HYDROXYETHYLAMINO) 9 ISOPROPYLPURINE; 6-((3-CHLORO)ANILINO)-2-(ISOPROPYL-2-HYDROXYETHYLAMINO)-9-ISOPROPYLPURINE; ADENINE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 1; DRUG DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; PURINE DERIVATIVE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL SURVIVAL; HELA CELL; HUMAN; MICROTUBULE ASSEMBLY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; ANIMAL; CELL CULTURE; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENETICS; METABOLISM; MITOSIS SPINDLE; MOUSE; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; TIME;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CDC2 PROTEIN KINASE; CELL CYCLE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HELA CELLS; HUMANS; MICE; MICE, KNOCKOUT; MICE, SCID; MICROTUBULE-ASSOCIATED PROTEINS; MITOTIC SPINDLE APPARATUS; NEOPLASM PROTEINS; PACLITAXEL; PHOSPHORYLATION; PURINES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036655052     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00084-3     Document Type: Article

References (53)

1. Altieri, D.C. (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7, 542-547.
2. Andersen, S.S.L. (2000). Spindle assembly and the art of regulating microtubule dynamics by MAPs and stathmin/Op18. Trends Cell Biol. 10, 261-267.
3. Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A.M., and Dimmeler, S. (2000). Posttraslational modification of Bcl-2 facilitates its proteasome-dependent degradation: Molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 20, 1886-1896.
4. Deveraux, Q.L., and Reed, J.C. (1999). IAP family proteins-suppressors of apoptosis. Genes Dev. 13, 239-252.
5. Fortugno, P., Wall, N.R., Giodini, A., O'Connor, D.S., Plescia, J., Padgett, K.M., Tognin, S., Marchisio, P.C., and Altieri, D.C. (2002). Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 115, 575-585.
6. Giodini, A., Kallio, M.J., Wall, N.R., Gorbsky, G.J., Tognin, S., Marchisio, P.C., Symons, M., and Altieri, D.C. (2002). Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62, 2462-2467.
7. Gray, N.S., Wodicka, L., Thunnissen, A.M., Norman, T.C., Kwon, S., Espinoza, F.H., Morgan, D.O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538.
8. Griffin, J. (2001). The biology of signal transduction inhibition: basic science to novel therapies. Semin. Oncol. 28, 3-8.
9. Grossman, D., Kim, P.J., Blanc-Brude, O.P., Brash, D.E., Tognin, S., Marchisio, P.C., and Altieri, D.C. (2001a). Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108, 991-999.
10. Grossman, D., Kim, P.J., Schechner, J.S., and Altieri, D.C. (2001b). Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 98, 635-640.
11. Hagtig, A., Karlsson, C., Clute, P., Jackman, M., and Pines, J. (1998). MPF localization is controlled by nuclear export. EMBO J. 17, 4127-4138.
12. Hakem, R., Hakem, A., Duncan, G.S., Henderson, J.T., Woo, M., Soengas, M.S., Elia, A., de la Pompa, J.L., Kagi, D., Khoo, W., et al. (1998). Differential requirement for caspase-9 in apoptotic pathways in vivo. Cell 94, 339-352.
13. Harvey, K.J., Lukovic, D., and Ucker, D.S. (2000). Caspase-dependent Cdk activity is a requisite effector of apoptotic death events. J. Cell Biol. 148, 59-72.
14. Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770-776.
15. Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S.J., and Mak, T.W. (2000). DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824-1827.
16. Huang, H., Joazeiro, C.A.P., Bonfoco, E., Kamada, S., Leverson, J.D., and Hunter, T. (2000). The inhibitor of apoptosis, c-IAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275, 26661-26664.
17. Itzhaki, J.E., Gilbert, C.S., and Porter, A.C.G. (1997). Construction by gene targeting in human cells of a "conditional" CDC2 mutant that rereplicates its DNA. Nat. Genet. 15, 258-265.
18. Kallio, M.J., Nieminen, M., and Eriksson, J.E. (2001). Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J. 15, 2721-2723.
19. Kanwar, J.R., Shen, W.P., Kanwar, R.K., Berg, R.W., and Krissansen, G.W. (2001). Effects of survivin antagonists on growth of established tumors and b7-1 immunogene therapy. J. Natl. Cancer Inst. 93, 1541-1552.
20. Kuttler, F., Valnet-Rabier, M.B., Angonin, R., Ferrand, C., Deconinck, E., Mougin, C., Cahn, J.Y., and Fest, T. (2002). Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16, 726-735.
21. Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C., and Altieri, D.C. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584.
22. Li, F., Ackermann, E.J., Bennett, C.F., Rothermel, A.L., Plescia, J., Tognin, S., Villa, A., Marchisio, P.C., and Altieri, D.C. (1999). Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1, 461-466.
23. Mesri, M., Wall, N.R., Li, J., Kim, R.W., and Altieri, D.C. (2001). Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981-990.
24. Motwani, M., Delohery, T.M., and Schwartz, G.K. (1999). Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. 5, 1876-1883.
25. Nicklas, R.B. (1997). How cells get the right chromosome. Science 275, 632-637.
26. cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 97, 13103-13107.
27. Olie, R.A., Simoes-Wust, A.P., Baumann, B., Leech, S.H., Fabbro, D., Stahel, R.A., and Zangemeister-Wittke, U. (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805-2809.
28. Ongkeko, W., Ferguson, D.J.P., Harris, A.L., and Norbury, C. (1995). Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. 108, 2897-2904.
29. Pines, J. (1999). Four-dimensional control of the cell cycle. Nat. Cell Biol. 1, E73-E79.
30. Reed, J.C., and Bischoff, J.R. (2000). BIRinging chromosomes through cell division-and survivin' the experience. Cell 102, 545-548.
31. Rowinsky, E.K., and Donehower, R.C. (1995). Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-1014.
32. Rudner, A.D., and Murray, A.W. (1996). The spindle assembly checkpoint. Curr. Opin. Cell Biol. 8, 773-780.
33. Sausville, E.A. (2002). Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 8, S32-S37.
34. Schwartz, G.K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., Maslak, P., Stoltz, M., Eden, L., Perkins, P., et al. (2002). Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with Paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 20, 2157-2170.
35. Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677.
36. cdc2 activation required for apoptosis. Science 263, 1143-1145.
37. Sorger, P.K., Dobles, M., Tournebize, R., and Hyman, A.A. (1997). Coupling cell division and cell death to microtubule dynamics. Curr. Biol. 9, 807-814.
38. Speliotes, E.K., Uren, A., Vaux, D., and Horvitz, H.R. (2000). The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol. Cell 6, 211-223.
39. Tao, W., Zhang, S., Turenchalk, G.S., Stewart, R.A., St. John, M.A.R., Chen, W., and Xu, T. (1999). Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat. Genet. 21, 177-181.
40. Theile, M., Seitz, S., Arnold, W., Jandrig, B., Frege, R., Schlag, P.M., Haensch, W., Guski, H., Winzer, K.J., Barrett, J.C., and Scherneck, S. (1996). A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 13, 677-685.
41. Tran, J., Master, Z., Yu, J.L., Rak, J., Dumont, D.J., and Kerbel, R.S. (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 99, 4349-4354.
42. van den Heuvel, S., and Harlow, E. (1993). Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054.
43. Vandre, D.D., and Borisy, G.G. (1989). Anaphase onset and and dephosphorylation of mitotic phosphoproteins occur concomitantly. J. Cell Sci. 94, 245-258.
44. Verdecia, M.A., Huang, H., Dutil, E., Kaiser, D.A., Hunter, T., and Noel, J.P. (2000). Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7, 602-608.
45. Wang, J., and Walsh, K. (1996). Resistance to apoptosis conferrred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361.
46. Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933.
47. Xia, H., Li, Y., Pei, J., Barton, J., Blackstad, M., Xu, T., and Tao, W. (2002). LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21, 1233-1241.
48. Yang, Y., Fang, S., Jensen, J.P., Weissman, A.M., and Ashwell, J.D. (2000). Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877.
49. Ye, K., Zhou, J., Landen, J.W., Bradbury, E.M., and Joshi, H.C. (2001). Sustained activation of p34cdc2 is required for noscapine-induced apoptosis. J. Biol. Chem. 276, 46697-46700.
50. Yoshida, H., Kong, Y.-Y., Yoshida, R., Elia, A.J., Hakem, A., Hakem, R., Penninger, J.M., and Mak, T.W. (1998). Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94, 739-750.
51. Cdc2 kinase. Mol. Cell 2, 581-591.
52. Yvon, A.-M.C., Wadsworth, P., and Jordan, M.A. (1999). Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947-959.
53. Zhao, J., Tenev, T., Martins, L.M., Downward, J., and Lemoine, N.R. (2000). The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113, 4363-4371.